On the other hand, the panel denied the idea of omitting surgery after a good response to neoadjuvant therapy, the importance of pCR for approving new treatments, the use of checkpoint inhibitors for patients with triple-negative stage 2 or 3 disease that have not been treated in the neoadjuvant setting, but receiving adjuvant chemotherapy, and finally adding pertuzumab for node-negative HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.